Company: PHAT
Filing Date: 2025-10-06
Form Type: 8-K
Source: 0001193125-25-230984
Chunk: 2

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-10-06
Form: 8-K
Item: Item 5.02
Chunk 2
---
 and (4) all unvested and outstanding time-based equity awards will become fully vested on the later of the date his release of claims becomes effective or the date of the change in control. All equity awards subject to performance-based vesting conditions will be governed by the terms of the applicable award agreement and equity plan under which such awards were granted.

All of Mr. Narula’s unvested and outstanding time-based equity awards will also become fully vested in the event of his death or his termination due to disability.

To the extent that any payment or benefit received in connection with a change in control would be subject to an excise tax under Section 4999 of the Internal Revenue Code, such payments and/or benefits will be subject to a “best pay cap” reduction if such reduction would result in a greater net after-taxbenefit to Mr. Narula than receiving the full amount of such payments.

Also in connection with his commencement of employment, effective October 6, 2025, the Company granted to Mr. Narula stock options to purchase 200,000 shares of the Company’s common stock. The stock options vest over a four year vesting schedule, with 25% of the stock options vesting on the first anniversary of Mr. Narula’s start date and the remaining stock options vesting in equal monthly installments thereafter, subject to Mr. Narula’s continued employment or service through the applicable vesting date. The stock options were granted under the Company’s 2019 Incentive Award Plan, and will have an exercise price equal to the closing price of the Company’s common stock on The Nasdaq Global Select Market on the date of grant. Also effective October 6, 2025, the Company granted to Mr. Narula 144,000 restricted stock units, which will vest over a period of three years in substantially equal annual installments, subject to Mr. Narula’s employment or service through the applicable vesting date (the “ RSUs”). The RSUs were also granted under the Company’s 2019 Incentive Award Plan.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                             PHATHOM PHARMACEUTICALS, INC.                           
  Date: October 6, 2025      By:                                /s/ Anne Marie Cook  
                                                                Anne Marie Cook      
                                                                Chief Legal Officer